Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors (GlobeNewswire, Plus Therapeutics Inc.) - Jan 2, 2020 - ""Plus' nanotechnology platform and DocePLUS Phase 2-ready orphan drug product candidate for small cell lung cancer have the potential to substantially improve the lives of patients battling cancer and rare diseases," commented Dr van Es-Johansson. "In addition to helping advance DocePLUS toward regulatory approval, I look forward to supporting the organization in further expanding and strengthening its pipeline to help more patients in need."."
Clinical • Regulatory
|